VIDEO: ASCO 2020 ‘incredibly exciting’ for lung cancer data

In this video, Nathan A. Pennell, MD, PhD, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, discusses presentations in lung cancer that he found interesting from this year’s virtual ASCO Annual Meeting.

“This is an incredibly exciting ASCO and there are a number of very exciting presentations in the lung cancer track for ASCO 2020,” Pennell said.

At the top of his list are the results from the ADAURA trial and the DESTINY study. He also expressed interest in a randomized study evaluating the use of tyrosine kinase inhibitors (TKIs) alone or in combination with ablative stereotactic radiation for patients with less than five metastatic sites of EGFR-mutated lung cancer.

Reference:

Herbst RS, et al. Abstract LBA5. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Siena S, et al. Abstract 4000. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Patel JD, et al. Abstract 9616. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Pennell reports serving in a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Cota Healthcare, Genentech, Inivata, Eli Lilly, Merck and Regeneron, and receiving research funding to his institution from Altor BioScience, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Jounce Therapeutics, Loxo, Merck, Pfizer and Spectrum Pharmaceuticals.

Take Homes in Lung Cancer

Read more

VIDEO: ASCO 2020 ‘incredibly exciting’ for lung cancer data

Reference:

Related Content